A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A single oral dose study to investigate the PK and safety of olorofim in subjects with severe
renal impairment compared to subjects with normal renal function.